Meprobamate
Carbamates
- Drug class
- Carbamates
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 1
- Products on record
- 1
- FDA reports (12 mo)
- 4
Overview
Plain-language summary, compiled from the cited regulatory records
Meprobamate is a medication classified as a carbamate [1]. It is approved for managing anxiety disorders and for the short-term relief of anxiety symptoms [1]. Anxiety or tension related to everyday stress typically does not require treatment with this type of medication [1]. The long-term effectiveness of meprobamate tablets, beyond four months, has not been established through systematic clinical studies [1]. Healthcare providers should periodically re-evaluate the medication's usefulness for each patient [1].
In the past 12 months, there have been 4 adverse event reports associated with meprobamate [2]. Some of the frequently reported adverse reactions include anuria, anxiety, arthralgia, decreased blood pressure, and dehydration [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 1 | June 19, 2021 |
USUnited States· FDA
1 product
Uses
INDICATIONS AND USAGE
Anxiety or tension associated with the stress of everyday life usually do not require treatment with an anxiolytic. The effectiveness of meprobamate tablets in long-term use, that is,more than 4 months, has not been assessed by systematic clinical studies.
The physician should periodically reassess the usefulness of the drug for the individual patient.
How to take
Drug interactions
Known interactions involving Meprobamate. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 325. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 17d814e2-b277-4d… · revised June 19, 2021 [PDF]
- [2]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.